BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 22907597)

  • 1. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
    Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
    Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.
    Agrawal AK; Chang PP; Feusner J
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):e1-4. PubMed ID: 21102354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Carr A; Tindall B; Penny R; Cooper DA
    AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
    Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
    Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
    Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
    Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
    Para MF; Finkelstein D; Becker S; Dohn M; Walawander A; Black JR
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):337-43. PubMed ID: 11015150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
    Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
    Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
    Park JW; Curtis JR; Moon J; Song YW; Kim S; Lee EB
    Ann Rheum Dis; 2018 May; 77(5):644-649. PubMed ID: 29092853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.